Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mitopower Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, HIBSHMAN, SARAH GRACE, who is also the busiest examiner with 1 busiest examiner pending action. The prosecution is currently limited to 1 distinct art unit, indicating a very focused entry into the patent system.
The concentration of the 1 pending office action under 1 distinct examiner means that the company's immediate success is tied to the review of HIBSHMAN, SARAH GRACE. Operating within the Biotechnology & Pharmaceuticals area often involves rigorous examination standards, and the use of 1 distinct art unit suggests the technology falls into a specific sub-category of that field. This lack of diversification across examiners or art units simplifies the management of the portfolio but increases the importance of this single interaction.
Practitioners should focus on the specific requirements of the assigned unit to ensure a favorable outcome. Since there is only 1 distinct examiner to communicate with, the company can develop a highly targeted response strategy. The 1 pending office action represents the entirety of the current active prosecution, making the performance in this technical field critical for the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBSHMAN, SARAH GRACE | 1 | 38.9% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18933620 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | HIBSHMAN, SARAH GRACE | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18933620 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | HIBSHMAN, SARAH GRACE | 1693 | §112DP | Non-Final OA | — | Pending | Oct 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial